CA Patent

CA3235985A1 — Methods and compositions for treating pulmonary hypertension

Assigned to Mannkind Corp · Expires 2023-05-04 · 3y expired

What this patent protects

Inhalable compositions for treating pulmonary hypertension comprising treprostinil, derivative thereof or analogs thereof and a method for treating pulmonary hypertension, pulmonary arterial hypertension and/or idiopathic pulmonary fibrosis are disclosed herein. Methods of manufa…

USPTO Abstract

Inhalable compositions for treating pulmonary hypertension comprising treprostinil, derivative thereof or analogs thereof and a method for treating pulmonary hypertension, pulmonary arterial hypertension and/or idiopathic pulmonary fibrosis are disclosed herein. Methods of manufacturing pharmaceutical compositions are also disclosed. Pharmaceutical compositions are based on crystalline diketopiperazine dry powders for pulmonary inhalation.

Drugs covered by this patent

Patent Metadata

Patent number
CA3235985A1
Jurisdiction
CA
Classification
—
Expires
2023-05-04
Drug substance claim
No
Drug product claim
No
Assignee
Mannkind Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.